EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Development of disease‐modifying therapies against Alzheimer's disease

Takeshi Iwatsubo iD

Psychiatry and Clinical Neurosciences · 2024-09 · 78 (9) · 491-494

DOI: 10.1111/pcn.13681 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Psychiatry and Clinical Neurosciences, online erschienen am 06.06.2024. Verfasst von Takeshi Iwatsubo. Beteiligte Einrichtung: Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To successfully develop disease‐modifying therapies (DMT) against Alzheimer's disease (AD), it is important to target the mild stage of the disease, before the pathological changes progress and dementia symptoms are fully manifested. To this end, the AD Neuroimaging Initiative (ADNI), a large‐scale observational study, was initiated in the U.S. with the goal of development of DMT that are effective in the early stages of mild cognitive impairment (MCI) by utilizing imaging and biomarkers. In Japan, J‐ADNI enrolled and followed up 537 patients, mainly with MCI, and established a platform for evaluation including amyloid PET, and demonstrated a high similarity in the clinical course of amyloid‐positive MCI (prodromal AD) in Japan and the U.S. In 2023, the anti‐Aβ antibody lecanemab successfully completed a Phase III clinical trial for early AD (prodromal AD + mild AD dementia) and was granted regulatory approval and made available both in the US and Japan. Also, phase III trial of donanemab was completed successful. The J‐TRC study was initiated in Japan as a “trial ready cohort (TRC)” consisting of participants who met the eligibility criteria for participation in preclinical and prodromal AD trials. Based on such a platform, the development of DMT for AD will progress more rapidly in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionHumansDrug DevelopmentProdromal Symptoms

Stichwörter der Autor:innen

Alzheimerdisease‐modifying therapy

Autor:innen und Institutionen

  • Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan.
  • National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Japan.

ORCID-Profile: Takeshi Iwatsubo

Zitieren

APA

Iwatsubo, T. (2024). Development of disease‐modifying therapies against Alzheimer's disease. Psychiatry and Clinical Neurosciences, 78(9), 491-494. https://doi.org/10.1111/pcn.13681

Vancouver

Iwatsubo T. Development of disease‐modifying therapies against Alzheimer's disease. Psychiatry and Clinical Neurosciences. 2024;78(9):491-494. doi:10.1111/pcn.13681

BibTeX
@article{Iwatsubo2024,
  author = {Iwatsubo, Takeshi},
  title = {Development of disease‐modifying therapies against Alzheimer's disease},
  journal = {Psychiatry and Clinical Neurosciences},
  year = {2024},
  volume = {78},
  number = {9},
  pages = {491--494},
  doi = {10.1111/pcn.13681}
}
Kostenlos starten →